Active substance
Results for the substance guselkumab
7 results
About this active substance
Guselkumab is a monoclonal antibody used for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. It works by blocking interleukin-23 (IL-23), a protein involved in the chronic inflammation associated with these conditions.
The medication is administered via subcutaneous injection, usually once every few weeks, as directed by a physician. Guselkumab has shown high efficacy in reducing skin lesions and joint symptoms.
Common side effects include upper respiratory tract infections, headaches, and injection site reactions. It is important for patients to be monitored for signs of infections or other complications.
Guselkumab provides a modern and effective option for patients with psoriasis and psoriatic arthritis, helping to improve their quality of life.
The medication is administered via subcutaneous injection, usually once every few weeks, as directed by a physician. Guselkumab has shown high efficacy in reducing skin lesions and joint symptoms.
Common side effects include upper respiratory tract infections, headaches, and injection site reactions. It is important for patients to be monitored for signs of infections or other complications.
Guselkumab provides a modern and effective option for patients with psoriasis and psoriatic arthritis, helping to improve their quality of life.
-
-
TREMFYA 100mg solution for injection CILAG ORIGINAL MEDICINE
-
TREMFYA 100mg ONEPRESS solution for injection in pre-filled pen CILAG ORIGINAL MEDICINE
-
TREMFYA 45mg/0.45ml solution for injection in pre-filled pen CILAG ORIGINAL MEDICINE
-
TREMFYA 100mg PUSHPEN solution for injection in pre-filled pen CILAG ORIGINAL MEDICINE
-
TREMFYA 200mg solution for injection in pre-filled pen CILAG ORIGINAL MEDICINE
-
TREMFYA 200mg concentrate for solution for infusion CILAG ORIGINAL MEDICINE